

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE Patent Examining Operations Patent Examining Operations | Column | C

Serial No:

09/807,810

Filed:

Title:

July 10, 2001

Examiner: Unassigned

Uses of Fibroblasts or Supernatants from Fibroblasts for the Suppression of Immune

Responses in Transplantation

Docket No.:

640100-416

Customer No.: 27162

TRANSMITTAL LETTER

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

SIR:

Enclosed please find the following:

- 1. Information Disclosure Statement;
- 2. Form PTO-1449;
- 3. Copies of references cited; and
- 4. A self-addressed, postage paid, return receipt postcard, date stamp and return of which is respectfully requested.

The Commissioner is authorized to charge payment of any additional filing fees required under 37 C.F.R. 1.16 associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

FIRST CLASS CERTIFICATE

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Respectfully submitted,

Raymond J. Lillie, Esq.

Reg. No. 31,778

CARELLA, BYRNE, BAIN, GILFILLAN, CECCHI, STEWART & OLSTEIN

Alle

Six Becker Farm Road

Roseland, New Jersey 07068

T: (973) 994-1700

F: (973) 994-1744



TECH CENTER 1600/2800 IN THE UNITED STATES PATENT AND TRADEMARK OFF

APPLICATION OF:

McIntosh, et al.

SERIAL NO:

09/807,810

GROUP ART UNIT:

1614

FILED:

July 10, 2001

EXAMINER:

Unassigned

CUSTOMER NO.:

27162

FOR:

Uses of Fibroblasts or Supernatants From Fibroblasts for the

Suppression of Immune Responses in Transplantation

ATTY/DKT NO.:

640100-416

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SIR:

Pursuant to 37 C.F.R. §1.56(a), Applicant(s) hereby cite(s) the enclosed documents listed on the attached copy of Form PTO-1449 which are believed to be material to the patentability of the above-identified application.

This Information Disclosure Statement is filed in accordance with the paragraph of 37 CFR §1.97 indicated below:


X §1.97(b) This Information Disclosure Statement is filed:

- Within three months of the filing date of a national (1) application; OR
- Within three months of the date of entry of the national stage **(2)** of an international application; OR
- Before the mailing of a first Office Action on the merits. (3) No fee or statement is required.

§1.97(c) This Information Disclosure Statement is filed after the period specified in paragraph (b) above, but before the mailing date of either:

- A Final Action or under 37 CFR §1.113; OR (1)
- A Notice of Allowance under 37 CFR §1.311; AND **(2)**

is accor	mpanied by either: (check one)
	The statement as specified in 37 CFR §1.97(e) set out below;
	OR
	The fee of \$180.00 under 37 CFR §1.17(p).



This Information Disclosure Statement is filed after the mailing date of the either:

- (1) a Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311;

BUT filed on or before payment of the Issue Fee; AND is accompanied by:

- (1) The statement as specified in 37 CFR §1.97(e) as set forth below; AND
- (2) Petition is hereby made under 37 CFR §1.97(d) for consideration of this Information Disclosure Statement; AND,
- (3) The petition fee of \$180.00 set out in 37 CFR §1.17(i).

§1.97(e)	The undersigned Attorney hereby states that:
_	each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement;
	or no item of information contained in this Information Disclosure Statement was cited in a first communication from a foreign patent office in a counterpart foreign application, or to the knowledge of the undersigned Attorney after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.

The Commissioner is authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

FIRST CLASS CERTIFICATE

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Raymond J. Lillie

Data

Respectfully submitted,

Reg. No. 31,778

CARELLA, BYRNE BAIN, GILFILLAN,

CECCHI, STEWART & OLSTEIN

Six Becker Farm Road

Roseland, NJ 07068 Tel: (973)994-1700

Fax: (973)994-1744

#187168 v1